Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Tensive raises €20M in debt funding from European Investment Bank to advance REGENERA biomaterial platform for breast reconstruction.
PRIVATESep 03, 2026•4 days ago
Amount Raised
€20 Million
Round Type
Debt Financing
MilanBiotechnologyHealth CareMedical Device
Investors
European Investment Bank
Description
Tensive S.r.l., a Milan-based clinical-stage advanced biomaterials medical device company, secured €20M in debt funding from the European Investment Bank (EIB). The company will use the funds to enhance R&D efforts, conduct clinical studies, obtain CE marking, and prepare for commercialization of REGENERA. Tensive develops bioresorbable, biomimetic polymeric scaffolds for breast reconstruction and tissue marking following lumpectomy or cosmetic procedures. The company maintains clinical evidence including 12-month follow-up data from a pivotal trial of 94 patients and five-year follow-up data from a first-in-human study.
Company Information
Company
Tensive S.r.l
Location
Milan, Lombardy, Italy
About
Tensive is a clinical-stage advanced biomaterials medical device company developing bioresorbable, biomimetic polymeric scaffolds for breast reconstruction and tissue marking. The company's platform delivers a bioresorbable implant designed to replace surgically removed tumors during lumpectomy procedures, which is gradually replaced by the patient's own natural tissue while preserving original breast shape and feel. Led by CEO Sanjay Kakkar, MD, Tensive maintains a maturing clinical evidence base including 12-month and five-year follow-up data from ongoing trials.
Don't miss Tensive S.r.l's next move
Get an email the moment Tensive S.r.l raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Predictive Intelligence
Strategic
ML-powered predictions for Tensive S.r.l's next move
MilanBiotechnologyHealth CareMedical Device